XORTX Therapeutics Inc XRTX
News
XORTX Patent Allowed for XRx-101 Program by Japan Patent Office
XORTX Outlines Anticipated Health Canada Clinical Trial Application for XRx-026 for Gout
XORTX Announces Planned FDA IND Submission for XRx-026 Gout Program Using XORLO™, Targeting USD$700M+ U.S. Gout Market Opportunity
XORTX Announces Initiation of Clinical and Commercial Manufacturing of XORLO™
XORTX Announces Termination and Postponement of Investor Relations Program
